Literature DB >> 23617364

Alterations of epigenetics and microRNA in hepatocellular carcinoma.

Yoshimasa Saito1, Sana Hibino, Hidetsugu Saito.   

Abstract

Studies have shown that alterations of epigenetics and microRNA (miRNA) play critical roles in the initiation and progression of hepatocellular carcinoma (HCC). Epigenetic silencing of tumor suppressor genes in HCC is generally mediated by DNA hypermethylation of CpG island promoters and histone modifications such as histone deacetylation, methylation of histone H3 lysine 9 (H3K9) and tri-methylation of H3K27. Chromatin-modifying drugs such as DNA methylation inhibitors and histone deacetylase inhibitors have shown clinical promise for cancer therapy. miRNA are small non-coding RNA that regulate expression of various target genes. Specific miRNA are aberrantly expressed and play roles as tumor suppressors or oncogenes during hepatocarcinogenesis. We and other groups have demonstrated that important tumor suppressor miRNA are silenced by epigenetic alterations, resulting in activation of target oncogenes in human malignancies including HCC. Restoring the expression of tumor suppressor miRNA by inhibitors of DNA methylation and histone deacetylase may be a promising therapeutic strategy for HCC.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  DNA methylation; epigenetics; hepatocellular carcinoma; histone modification; miRNA

Year:  2013        PMID: 23617364     DOI: 10.1111/hepr.12147

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  20 in total

1.  Developmental exposure to valproic acid alters the expression of microRNAs involved in neurodevelopment in zebrafish.

Authors:  Neelakanteswar Aluru; Kristina L Deak; Matthew J Jenny; Mark E Hahn
Journal:  Neurotoxicol Teratol       Date:  2013-10-12       Impact factor: 3.763

2.  miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2.

Authors:  Chunfang Zhao; Ya Li; Ming Zhang; Yi Yang; Li Chang
Journal:  Hum Cell       Date:  2015-01-14       Impact factor: 4.174

3.  DNA methylation-mediated repression of miR-941 enhances lysine (K)-specific demethylase 6B expression in hepatoma cells.

Authors:  Pei-Pei Zhang; Xiang-Ling Wang; Wei Zhao; Bing Qi; Qian Yang; Hai-Ying Wan; Ze-Yu Shuang; Min Liu; Xin Li; Shengping Li; Hua Tang
Journal:  J Biol Chem       Date:  2014-07-21       Impact factor: 5.157

4.  Molecular Pathogenesis of Hepatocellular Carcinoma.

Authors:  Daniel Wai-Hung Ho; Regina Cheuk-Lam Lo; Lo-Kong Chan; Irene Oi-Lin Ng
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

5.  Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703.

Authors:  Baoqiang Wu; Yong Jiang; Feng Zhu; Donglin Sun; Hongjun Huang
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

Review 6.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

7.  Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.

Authors:  S Hibino; Y Saito; T Muramatsu; A Otani; Y Kasai; M Kimura; H Saito
Journal:  Oncogenesis       Date:  2014-05-26       Impact factor: 7.485

Review 8.  Long non-coding RNAs: critical players in hepatocellular carcinoma.

Authors:  Jin Sun; Beibei Bie; Shu Zhang; Jun Yang; Zongfang Li
Journal:  Int J Mol Sci       Date:  2014-11-07       Impact factor: 5.923

9.  MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.

Authors:  Bijing Mao; He Xiao; Zhimin Zhang; Dong Wang; Ge Wang
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

10.  Identification of the collagen type 1 α 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma.

Authors:  Masamichi Hayashi; Shuji Nomoto; Mitsuhiro Hishida; Yoshikuni Inokawa; Mitsuro Kanda; Yukiyasu Okamura; Yoko Nishikawa; Chie Tanaka; Daisuke Kobayashi; Suguru Yamada; Goro Nakayama; Tsutomu Fujii; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Shin Takeda; Yasuhiro Kodera
Journal:  BMC Cancer       Date:  2014-02-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.